Home>Topics>Companies>Dendreon Corporation

Dendreon Corporation

  1. All
  2. Commentary
  3. Headlines
  1. Dendreon Announces Chapter 11 Bankruptcy Filing; Discontinuing Coverage

    Commentary

    Thu, 20 Nov 2014

    cancer drug business. This news is not surprising, given the overhang from the $620 million in notes that were coming due in 2016, as the company continued to remain unprofitable despite Provenge sales of about $150 million last year.

  2. Dendreon Announces Chapter 11 Bankruptcy Filing; Placing Company Under Review

    Commentary

    Mon, 10 Nov 2014

    cancer drug business. This news is not surprising given the overhang from the $620 million in notes that were coming due in 2016, as the company continued to remain unprofitable despite Provenge sales of about $150 million last year.

  3. Second-Quarter Provenge Sales Are Solid; Convertible Debt Overhang Underscores Serious Risks

    Commentary

    Tue, 12 Aug 2014

    Dendreon reported second-quarter results ..... than our expectations, with solid Provenge sales. However, the ongoing lack ..... no-moat, negative trend ratings. Dendreon reported $82.2 million in Provenge sales for the quarter, a solid

  4. Another Quarter of Sluggish Provenge Sales; Convertible Debt Overhang Underscores Risks

    Commentary

    Fri, 9 May 2014

    Dendreon reported first-quarter results ..... expectations, with continued sluggish Provenge sales and lack of clarity on plans ..... no-moat, negative trend ratings. Dendreon reported $68.8 million in Provenge sales for the quarter, a slight

  5. Dendreon 4Q Results Show Stabilization of Sales and Highlight European Opportunity; Maintaining FVE

    Commentary

    Mon, 3 Mar 2014

    Dendreon reported fourth-quarter results ..... expectations. The stabilization of Provenge revenue and the announcement of ..... estimate and our no-moat rating. Dendreon reported $74.8 million in Provenge sales for the quarter, up 10

  6. Dendreon shares jump on news of prostate drug's European launch

    Headlines

    Mon, 3 Mar 2014

    (Reuters) - Biotechnology company Dendreon Corp said it would start selling its prostate cancer vaccine Provenge in Europe, sending its shares up nearly 15 percent in premarket trading.

  7. Dendreon's 4Q Provenge Sales Slightly Better Than Expected; Maintaining Fair Value Estimate

    Commentary

    Mon, 13 Jan 2014

    Dendreon on Monday announced preliminary Provenge revenue for the fourth quarter ..... increasing competition in Provenge 's prechemotherapy indication ..... the current trajectory of Provenge 's sales, we think Dendreon will need to tap the equity

  8. Lowering Dendreon's Fair Value Estimate on Lower Provenge Assumptions

    Commentary

    Fri, 9 Aug 2013

    Dendreon reported second-quarter ..... its sole product, Provenge , due to ongoing ..... able to increase Provenge sales over last year ..... Additionally, Dendreon disclosed that CFO ..... a decrease in our Provenge sales expectations

  9. Dendreon Receives Positive EU Opinion for Provenge ; No Change to Fair Value Estimate or Moat Rating

    Commentary

    Fri, 28 Jun 2013

    Dendreon DNDN announced that it received ..... Agency for the approval of Provenge , the firm's immunotherapy ..... this year, and we expect Dendreon to announce its commercialization ..... European launch this year. If Provenge does succeed in gaining

  10. Provenge Sales Plummet in Dendreon's First Quarter

    Commentary

    Thu, 9 May 2013

    Dendreon DNDN reported dismal first-quarter ..... sales of its sole product Provenge plummet amid new competition ..... space. Though we believe Dendreon 's first quarter will be ..... these results as a clue to Provenge 's ultimate role within

« Prev1234Next »
Content Partners